Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial
Top Cited Papers
- 17 March 2025
- journal article
- Published by Elsevier in The Lancet Oncology
- Vol. 26 (4) , 425-436
Abstract
No abstract availableKeywords
Funding Information
- Dutch Cancer Society
- Netherlands Organisation for Health Research and Development
This publication has 19 references indexed in Scilit:
- Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trialAnnals of Oncology, 2023
- Early versus delayed surgery following neoadjuvant chemoradiation for esophageal cancer: a systematic review and meta-analysisEsophagus, 2023
- Use of a non-endoscopic immunocytological device (Cytosponge™) for post chemoradiotherapy surveillance in patients with oesophageal cancer in the UK (CYTOFLOC): A multicentre feasibility studyeClinicalMedicine, 2022
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerNew England Journal of Medicine, 2021
- Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal CancerGastroenterology, 2020
- Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort studyThe Lancet Oncology, 2018
- Patients' preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancerBritish Journal of Surgery, 2018
- Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancerBritish Journal of Cancer, 2014
- Reporting of Noninferiority and Equivalence Randomized TrialsJAMA, 2012
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerNew England Journal of Medicine, 2012